[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Based on the patient's symptoms, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).\n\nHere's a summary of the key points that support this diagnosis:\n\n1. **HIV infection with low CD4+ count**: The patient's immunocompromised state increases her risk for opportunistic infections and malignancies, including PCNSL.\n2. **Neurological symptoms**: Headaches, blurred vision, confusion, ataxia, and memory impairment are common symptoms of PCNSL.\n3. **Cerebrospinal fluid (CSF) analysis**: Lymphocytic predominant pleocytosis is consistent with PCNSL, and the presence of Epstein-Barr virus (EBV) DNA in the CSF supports the diagnosis, as EBV is associated with PCNSL in immunocompromised patients.\n4. **MRI findings**: The solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum is consistent with PCNSL. The lesion's location and appearance are typical for this diagnosis.\n5. **Exclusion of other diagnoses**: The patient's symptoms and laboratory results are less consistent with other diagnoses, such as toxoplasmosis (which is more common in HIV patients with low CD4+ counts, but typically presents with multiple ring-enhancing lesions) or progressive multifocal leukoencephalopathy (PML, which typically presents with diffuse white matter lesions).\n\nPCNSL is a rare and aggressive non-Hodgkin lymphoma that arises in the brain, eyes, or spinal cord. It is more common in immunocompromised individuals, such as those with HIV/AIDS. Treatment typically involves chemotherapy, radiation therapy, or a combination of both, and may also include antiretroviral therapy to improve the patient's immune function.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is Enfuvirtide (T-20), also known as Fuzeon. However, this is not typically a first-line treatment for HIV.\n\nA more commonly prescribed medication that targets the gp41 subunit is a class of drugs known as HIV fusion inhibitors, but specifically, the one that is most well-known is Enfuvirtide. It works by binding to the gp41 subunit, preventing the fusion of the viral envelope with the host cell membrane, thereby inhibiting viral entry into the host cell.\n\nIt's worth noting that Enfuvirtide is typically used in combination with other anti-retroviral medications and is often reserved for patients who have failed other treatments or have multi-drug resistant HIV strains. First-line treatments for HIV typically involve a combination of medications from other classes, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A mother with HIV has given birth to a healthy boy 2 days ago. She takes her antiretroviral medication regularly and is compliant with the therapy. Before being discharged, her doctor explains that she cannot breastfeed the child since there is a risk of infection through breastfeeding and stresses that the child can benefit from formula feeding. The physician stresses the importance of not overheating the formula since Vitamin C may be inactivated by overheating. What molecular process could be impaired if the mother boiled the formula longer than needed?",
    "answer": "If the mother boiled the formula longer than needed, the molecular process that could be impaired is denaturation of proteins and degradation/inactivation of heat-sensitive nutrients, particularly Vitamin C (ascorbic acid).\n\nVitamin C is a water-soluble vitamin that is sensitive to heat, water, and oxygen. When formula is boiled for an extended period, the heat can cause the Vitamin C molecules to break down or degrade, leading to a loss of its nutritional value. This process is an example of thermal degradation.\n\nIn more detail, the heat from boiling can cause the Vitamin C molecules to undergo a series of chemical reactions, including:\n\n1. Hydrolysis: The heat can break the chemical bonds in the Vitamin C molecule, leading to the formation of smaller, inactive compounds.\n2. Oxidation: The heat can also cause the Vitamin C molecules to react with oxygen in the air, leading to the formation of inactive compounds.\n3. Decarboxylation: The heat can cause the Vitamin C molecule to lose its carboxyl group, leading to the formation of an inactive compound.\n\nAs a result of these reactions, the Vitamin C in the formula can become inactivated, reducing its nutritional value and potential health benefits for the child.\n\nIt's worth noting that the World Health Organization (WHO) recommends that formula be prepared with boiled water, but the boiling time should be limited to 1-2 minutes to minimize the loss of heat-sensitive nutrients like Vitamin C. After boiling, the formula should be cooled to a safe temperature before feeding the child.",
    "true_answer": "If the formula is boiled longer than needed, resulting in the inactivation of Vitamin C, then collagen synthesis could be impaired."
  },
  {
    "question": "A 35-year-old woman presents to a physician\u2019s office for a follow-up visit. She recently underwent a complete physical examination with routine laboratory tests. She also had a Pap smear and testing for sexually transmitted diseases. Since her divorce 2 years ago, she had sexual encounters with random men at bars or social events and frequently did not use any form of protection during sexual intercourse. She was shown to be positive for the human immunodeficiency virus (HIV). Combination anti-retroviral treatment is initiated including zidovudine, didanosine, and efavirenz. One week later, she is rushed to the hospital where she is diagnosed with acute pancreatitis. What precautions in her medication will be required after pancreatitis resolves with treatment?",
    "answer": "Given the patient's diagnosis of acute pancreatitis following the initiation of combination anti-retroviral treatment (ART) including zidovudine, didanosine, and efavirenz, it is crucial to identify which medication might have contributed to the pancreatitis. Didanosine is known to have a side effect of causing pancreatitis, and this risk is increased when it is used in combination with other nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine.\n\nTo manage the patient's HIV infection while minimizing the risk of recurrent pancreatitis, the following precautions and adjustments in her medication regimen should be considered:\n\n1. **Discontinue Didanosine:** Given its association with pancreatitis, discontinuing didanosine is a priority. This will help prevent further episodes of pancreatitis.\n\n2. **Alternative NRTI Options:** The patient's regimen can be modified by replacing didanosine with another NRTI that has a lower risk of pancreatitis. Options might include tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), or abacavir (ABC), depending on the patient's viral resistance profile and other factors.\n\n3. **Maintain Efavirenz:** Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is not typically associated with pancreatitis. It can likely be continued as part of the patient's regimen, assuming there are no other contraindications or adverse effects.\n\n4. **Zidovudine Considerations:** While zidovudine can cause various side effects, pancreatitis is less commonly associated with it compared to didanosine. However, considering the patient's recent pancreatitis, the healthcare provider might consider replacing zidovudine with another NRTI to minimize any potential risk, especially if the patient is at increased risk for mitochondrial toxicity or other zidovudine-related adverse effects.\n\n5. **Monitor for Pancreatitis Symptoms:** After adjusting the medication regimen, it's essential to closely monitor the patient for any signs or symptoms of pancreatitis recurrence, such as abdominal pain, nausea, vomiting, or elevated pancreatic enzymes.\n\n6. **Regular Follow-Up:** Regular follow-up appointments with the healthcare provider are crucial to assess the patient's response to the new regimen, monitor for any side effects, and adjust the treatment plan as necessary to ensure optimal management of her HIV infection while preventing further episodes of pancreatitis.\n\nBy taking these precautions and adjusting the medication regimen, the healthcare provider can help minimize the risk of recurrent pancreatitis while effectively managing the patient's HIV infection.",
    "true_answer": "After resolving pancreatitis, didanosine should be replaced with lamivudine to avoid recurrence."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The most likely target of the antibody being designed by the physician scientist is the gp120 protein, which is part of the HIV envelope.\n\nThe HIV envelope is composed of two main proteins: gp120 and gp41. gp120 is the surface protein that binds to CD4 receptors on host cells, while gp41 is the transmembrane protein that facilitates fusion of the viral envelope with the host cell membrane.\n\nThe natural humoral immune response to HIV infection typically targets the gp120 protein, as it is the most exposed and accessible part of the viral envelope. Antibodies against gp120 can neutralize the virus by blocking its binding to CD4 receptors, thereby preventing infection.\n\nThe ELISA and western blot assays used to diagnose HIV infection also typically detect antibodies against the gp120 and gp41 proteins. Therefore, it is likely that the physician scientist is trying to generate a new, more potent antibody against the gp120 protein, which is a key target of the natural humoral immune response to HIV infection.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "Based on the presentation of fever, hemoptysis, and a fibrocavitary lesion in the lung, along with the finding of septate hyphae that branch at acute angles on biopsy, the most likely causal organism is Aspergillus.\n\nAspergillus is a type of fungus that can cause a range of diseases, including aspergillosis, which can manifest as a pulmonary infection. The presence of septate hyphae that branch at acute angles (typically 45-degree angles) is characteristic of Aspergillus species.\n\nIn an HIV-positive individual, the immune system is compromised, making them more susceptible to opportunistic infections, including fungal infections like aspergillosis. The fibrocavitary lesion in the lung is also consistent with an aspergillosis infection, particularly in an immunocompromised host.\n\nOther possibilities, such as Mucorales (which cause mucormycosis) or other fungi, are less likely given the description of the hyphae and the clinical presentation. Mucorales typically have non-septate or pauciseptate hyphae that branch at right angles, whereas Aspergillus has septate hyphae that branch at acute angles.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The addition of valganciclovir to the patient's current medication regimen, which includes zidovudine, lamivudine, and dolutegravir, puts the patient at greatest risk for hematologic adverse effects, particularly neutropenia.\n\nValganciclovir is a cytomegalovirus (CMV) antiviral medication that can cause bone marrow suppression, leading to neutropenia, anemia, and thrombocytopenia. Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) used in antiretroviral therapy, also has a well-known side effect of bone marrow suppression, which can lead to neutropenia and anemia.\n\nThe combination of valganciclovir and zidovudine increases the risk of hematologic adverse effects due to their overlapping toxicities. Therefore, the patient should be closely monitored for signs of neutropenia, anemia, and thrombocytopenia, and his complete blood count (CBC) should be regularly checked while on this combination therapy.\n\nLamivudine and dolutegravir are less likely to contribute to hematologic adverse effects, but it is still important to monitor the patient's laboratory values and adjust the treatment regimen as needed to minimize the risk of adverse effects.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "For a newborn suspected of being exposed to HIV, the most appropriate diagnostic test is the HIV DNA polymerase chain reaction (PCR) test. This test directly detects the genetic material of the virus and can identify HIV infection in infants as young as a few days old.\n\nHere's why HIV DNA PCR is preferred over other tests in this scenario:\n\n1. **HIV Antibody Tests**: These tests detect the presence of antibodies against HIV, which are passed from mother to child. However, these antibodies can persist in the infant's bloodstream for up to 18 months, regardless of whether the child is actually infected. Therefore, an antibody test cannot distinguish between the presence of maternal antibodies and an actual infection in the newborn.\n\n2. **HIV RNA PCR (Viral Load Test)**: This test measures the amount of HIV RNA in the blood, indicating the level of viral activity. While it can be used to diagnose HIV infection, it's more commonly used to monitor the effectiveness of antiretroviral therapy in individuals already known to be infected.\n\n3. **HIV DNA PCR**: This is the preferred test for diagnosing HIV infection in newborns. It detects the HIV proviral DNA integrated into the host's cells, providing direct evidence of infection. The test can be performed as early as a few days after birth and is highly sensitive and specific for diagnosing HIV infection in infants.\n\nGiven the patient's concern about the transmission of HIV to her baby, the HIV DNA PCR test is the most appropriate choice because it can directly diagnose HIV infection in the newborn, allowing for early initiation of antiretroviral therapy if necessary, which significantly improves the child's prognosis.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This is a complex and sensitive situation, requiring careful consideration of the patient's confidentiality, the risk to his wife, and the physician's ethical and legal obligations. Here's the most appropriate next step:\n\nThe physician should inform the patient that, while confidentiality is essential in the physician-patient relationship, there are certain situations where disclosure is necessary to prevent harm to others. In this case, the patient's wife is at risk of acquiring HIV, and the physician has a duty to protect her.\n\nThe physician should:\n\n1. **Counsel the patient**: Explain the risks of HIV transmission to his wife and the importance of disclosing his diagnosis to her. Emphasize that this is not only a moral obligation but also a public health imperative to prevent further transmission.\n2. **Encourage the patient to disclose**: Urge the patient to inform his wife about his HIV diagnosis and encourage him to do so in a timely manner. Offer to support the patient in this process, if needed.\n3. **Offer to facilitate disclosure**: If the patient is unwilling or unable to disclose his diagnosis to his wife, the physician should offer to facilitate the disclosure process, while still maintaining patient confidentiality. This can be done by:\n\t* Obtaining the patient's consent to disclose his diagnosis to his wife.\n\t* Informing the wife of the potential risk, without revealing the patient's identity (e.g., \"I have a patient who has been diagnosed with HIV, and I believe you may be at risk\").\n\t* Providing the wife with information about HIV testing and counseling.\n4. **Report to public health authorities (if necessary)**: If the patient refuses to disclose his diagnosis to his wife, and the physician believes that the wife is at significant risk of acquiring HIV, the physician may need to report the case to public health authorities. This is typically done to prevent further transmission and to ensure that the wife receives appropriate testing and care.\n5. **Document the conversation**: The physician should document the conversation with the patient, including the discussion about disclosure and the patient's response.\n\nIt's essential to note that the specific laws and regulations regarding confidentiality and disclosure vary by jurisdiction. The physician should be familiar with the relevant laws and regulations in their area and consult with a medical ethics expert or attorney if needed. Ultimately, the physician's primary responsibility is to protect the patient's confidentiality while also ensuring the safety and well-being of others who may be at risk.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old HIV-positive male presents to the ER with a 4-day history of headaches and nuchal rigidity. A lumbar puncture shows an increase in CSF protein and a decrease in CSF glucose. When stained with India ink, light microscopy of the patient\u2019s CSF reveals encapsulated yeast with narrow-based buds. Assuming a single pathogenic organism is responsible for this patient\u2019s symptoms, what diagnostic test results would also be expected in this patient?",
    "answer": "Based on the presentation and laboratory findings, the patient is likely suffering from cryptococcal meningitis, caused by the encapsulated yeast Cryptococcus neoformans.\n\nThe expected diagnostic test results in this patient would include:\n\n1. **Positive Cryptococcal Antigen (CRAG) test**: This is a latex agglutination test that detects the presence of cryptococcal capsular antigen in the CSF or serum. The test is highly sensitive and specific for cryptococcal infection.\n2. **Positive culture for Cryptococcus neoformans**: The CSF sample can be cultured on a suitable medium, such as Sabouraud agar, to isolate and identify the yeast.\n3. **Elevated CSF opening pressure**: Cryptococcal meningitis can cause increased intracranial pressure, which would be reflected in an elevated CSF opening pressure measured during the lumbar puncture.\n4. **CSF pleocytosis with lymphocytic predominance**: The CSF may show an increased white blood cell count with a predominance of lymphocytes, indicating an inflammatory response to the infection.\n5. **Immunocompromised status confirmation**: As the patient is already known to be HIV-positive, further testing may include CD4 cell count and viral load measurements to assess the severity of immunosuppression.\n\nThe India ink stain, which reveals encapsulated yeast with narrow-based buds, is a classic diagnostic feature of Cryptococcus neoformans. The combination of clinical presentation, laboratory findings, and diagnostic test results would support a diagnosis of cryptococcal meningitis in this patient.",
    "true_answer": "A latex agglutination test specific for Cryptococcal meningitis would also be expected in this patient."
  },
  {
    "question": " What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?",
    "answer": "Studying microRNAs (miRNAs) as therapeutic targets in HIV patients requires a comprehensive and multi-disciplinary approach. Here's a suggested methodological framework:\n\n**Preclinical Studies**\n\n1. **miRNA profiling**: Use high-throughput sequencing (e.g., Illumina, Ion Torrent) or microarray analysis to identify differentially expressed miRNAs in HIV-infected cells, tissues, or bodily fluids (e.g., blood, cerebrospinal fluid).\n2. **Bioinformatics analysis**: Utilize computational tools (e.g., TargetScan, miRBase) to predict miRNA targets and potential regulatory networks involved in HIV infection.\n3. **In vitro experiments**: Validate miRNA targets and investigate their functional roles in HIV replication, latency, and immune response using cellular models (e.g., CD4+ T cells, macrophages).\n4. **In vivo studies**: Use animal models (e.g., humanized mice, non-human primates) to investigate the effects of miRNA modulation on HIV infection and disease progression.\n\n**Clinical Studies**\n\n1. **Patient recruitment**: Enroll HIV-infected patients with diverse clinical characteristics (e.g., treatment-naive, antiretroviral therapy-experienced, with or without co-infections).\n2. **Sample collection**: Collect blood, tissue, or other bodily fluid samples to analyze miRNA expression profiles and correlate them with clinical parameters (e.g., viral load, CD4+ T cell count).\n3. **Longitudinal studies**: Conduct repeated sample collections and analyses to monitor changes in miRNA expression and their association with disease progression or response to antiretroviral therapy.\n4. **Interventional studies**: Design clinical trials to evaluate the safety and efficacy of miRNA-based therapeutics (e.g., miRNA mimics, inhibitors) in HIV patients.\n\n**Therapeutic Targeting of miRNAs**\n\n1. **miRNA modulation**: Use synthetic miRNA mimics or inhibitors to modulate miRNA expression in HIV-infected cells or tissues.\n2. **Delivery systems**: Develop and test delivery systems (e.g., nanoparticles, liposomes, viral vectors) to efficiently deliver miRNA therapeutics to target cells or tissues.\n3. **Combination therapy**: Investigate the potential of combining miRNA-based therapeutics with existing antiretroviral therapies to enhance treatment efficacy or reduce toxicity.\n\n**Essential Considerations**\n\n1. **miRNA stability and specificity**: Ensure that miRNA targets are stable and specific to HIV-infected cells or tissues to minimize off-target effects.\n2. **Safety and toxicity**: Assess the safety and potential toxicity of miRNA-based therapeutics in preclinical and clinical studies.\n3. **Biomarker development**: Identify and validate miRNA biomarkers to monitor treatment response, disease progression, or potential side effects.\n4. **Collaboration and data sharing**: Foster collaboration among researchers, clinicians, and industry partners to accelerate the development of miRNA-based therapeutics for HIV treatment.\n\nBy following this methodological framework, researchers can comprehensively investigate the role of miRNAs as therapeutic targets in HIV patients and develop effective treatments to improve patient outcomes.",
    "true_answer": "To study microRNAs as therapeutic targets in HIV patients, the best methodological approach would likely include a combination of in vitro experiments, in vivo animal models, and clinical trials . Initial in vitro experiments would involve the use of HIV-infected cell lines or primary cells to study the function and expression of specific microRNAs in relation to HIV replication and pathogenesis . This research would provide insights into the potential roles of microRNAs in HIV infection and help identify candidate microRNAs for therapeutic targeting . Next, in vivo animal models, such as humanized mice, should be employed to study the effects of modulating specific microRNAs on HIV infection and disease progression . These models would help evaluate the safety and efficacy of potential microRNA-based therapies, as well as investigate the potential for off-target effects and immunogenicity . Techniques such as delivery of microRNA mimics or antagomirs, viral vector-mediated overexpression or knockdown, and CRISPR-Cas9 editing can be used to manipulate microRNA expression in these models  . Finally, clinical trials should be conducted to validate the safety, efficacy, and tolerability of potential microRNA-based therapies in HIV patients . These trials would involve the enrollment of HIV-positive patients to receive the experimental treatment(s) under controlled conditions, with rigorous monitoring of viral load, treatment-related adverse events, immune function, and other relevant parameters . The results of these clinical trials would be instrumental in determining the clinical feasibility of microRNA-based therapies for treating HIV infections ."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "DNA methylation is a crucial epigenetic mechanism that plays a significant role in regulating gene expression, including in the context of HIV-1 infection. Research has shown that DNA methylation profiles are altered in patients with latent HIV-1 or active infection. Here are some key findings:\n\n**Latent HIV-1 infection:**\n\n1. **Hypermethylation of HIV-1 promoter**: In latently infected cells, the HIV-1 promoter is often hypermethylated, which suppresses viral transcription and contributes to the latent state.\n2. **Methylation of host genes**: Latent HIV-1 infection is also associated with changes in the methylation status of host genes involved in immune response, cell cycle regulation, and apoptosis.\n3. **Epigenetic silencing**: Latent HIV-1 proviruses are often epigenetically silenced through the combined action of DNA methylation, histone modifications, and chromatin remodeling.\n\n**Active HIV-1 infection:**\n\n1. **Hypomethylation of HIV-1 promoter**: In actively infected cells, the HIV-1 promoter is often hypomethylated, which allows for active viral transcription and replication.\n2. **Methylation of host genes**: Active HIV-1 infection is associated with changes in the methylation status of host genes involved in immune response, inflammation, and cell survival.\n3. **Global DNA hypomethylation**: HIV-1 infection can lead to global DNA hypomethylation, which may contribute to the activation of endogenous retroviruses and the disruption of host gene expression.\n\n**Common features:**\n\n1. **Changes in DNA methylation patterns**: Both latent and active HIV-1 infections are characterized by changes in DNA methylation patterns, which can influence viral gene expression and the host response to infection.\n2. **Epigenetic regulation of viral latency**: DNA methylation plays a crucial role in regulating viral latency, with hypermethylation contributing to the suppression of viral transcription and hypomethylation allowing for active viral replication.\n3. **Impact on host gene expression**: HIV-1 infection can alter the methylation status of host genes, leading to changes in gene expression that may contribute to the pathogenesis of the disease.\n\n**Therapeutic implications:**\n\n1. **Epigenetic therapy**: Targeting DNA methylation and other epigenetic mechanisms may provide a novel approach to treating HIV-1 infection, particularly in the context of latent infection.\n2. **Latency reversal**: Understanding the epigenetic mechanisms underlying viral latency may inform the development of latency-reversing therapies, which aim to reactivate latent viruses and make them susceptible to antiretroviral therapy.\n3. **Personalized medicine**: Analyzing DNA methylation profiles in HIV-1-infected individuals may help identify biomarkers for disease progression and treatment response, ultimately enabling personalized treatment approaches.\n\nIn summary, DNA methylation profiles are altered in patients with latent HIV-1 or active infection, with changes in the methylation status of both viral and host genes contributing to the regulation of viral gene expression and the host response to infection. Further research is needed to fully understand the mechanisms underlying these changes and to explore the therapeutic potential of targeting epigenetic mechanisms in HIV-1 infection.",
    "true_answer": "I searched for your question and found some relevant results. According to these results, **DNA methylation** is a possible mechanism that regulates the **latency** and **reactivation** of **HIV-1 provirus** in infected cells  . However, the **methylation profiles** of HIV-1 proviral DNA may vary depending on the **disease progression**, **antiretroviral therapy**, and **cell type** of the patients ."
  }
]